A retrospective study of ibrutinib in patients with relapsed chronic-lymphocytic-leukaemia after allogeneic stem cell transplantation

Trial Profile

A retrospective study of ibrutinib in patients with relapsed chronic-lymphocytic-leukaemia after allogeneic stem cell transplantation

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Feb 2016

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Feb 2016 New trial record
    • 11 Jan 2016 Results (n=5, cutoff date 12 November 2015) published in the Bone Marrow Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top